Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Remibrutinib1件: Remibrutinib (Remibrutinib)1件: Remibrutinib (Remibrutinib) 💬 1件: BTK 💬 7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 11, 13, 53 💬
2Remibrutinib (Blinded)1件: Remibrutinib (Remibrutinib)1件: Remibrutinib (Remibrutinib) 💬 1件: BTK 💬 7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬2件: 11, 13 💬
3Remibrutinib (Open Label)1件: Remibrutinib (Remibrutinib)1件: Remibrutinib (Remibrutinib) 💬 1件: BTK 💬 7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬2件: 11, 13 💬
4Remibrutinib oral treatment1件: Remibrutinib (Remibrutinib)1件: Remibrutinib (Remibrutinib) 💬 1件: BTK 💬 7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬1件: 13 💬